Gurnet Point Capital, a healthcare-focused fund, has named Dr. Sophie Kornowski as senior partner. Currently, she’s the executive vice president of Roche Partnering.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gurnet Point Capital (“Gurnet Point”) today announced that Dr. Sophie Kornowski is to be appointed as Senior Partner. Dr. Kornowski currently serves as Executive Vice-President of Roche Partnering, where she focuses on establishing external partnerships with biotechnology and research institutions worldwide for Roche Holding AG, one of the world’s largest healthcare companies. She is also a member of Roche’s Extended Global Executive Committee. Dr. Kornowski will continue as a member of the Board of Directors of Chugai Pharmaceutical Co Ltd in Japan upon joining Gurnet Point.
Commenting on Dr. Kornowski’s appointment, Gurnet Point Managing Partner Christopher A. Viehbacher said: “Sophie will be joining Gurnet Point Capital at an incredibly exciting time. With a solid foundation of portfolio companies to build upon and significant capital still to invest, Sophie’s deep operational leadership experience in combination with her expertise in finding attractive acquisition targets will give additional strength to our growth. My team and I look forward to working with her very much.”
Dr. Sophie Kornowski, said: ”Given their combined experience in the sector and with Ernesto Bertarelli’s vision, and under Chris Viehbacher’s executive leadership, Gurnet Point Capital is uniquely positioned to build a new generation of companies eager to bring meaningful innovation to patients and the healthcare system. I am looking forward to working with the team and applying my experience in this entrepreneurial environment, to not only identify exciting opportunities, but also to support the growth of Gurnet Point’s existing and future portfolio companies.”
Dr. Kornowski and her team completed over 50 deals per year in her current role as head of partnering at Roche. Previously, she led Roche’s major affiliate for five years in France. Dr. Kornowski also spent 11 years in various leadership roles at Merck in the United States, France and Israel. She spent the early years of her career at Abbott and Sanofi, in France and the United States. Dr. Kornowski has an MBA from the University of Chicago Booth and a PhD in Pharmacy from Paris Descartes University.
Following her departure from Roche, Dr. Kornowski initially will be based in Geneva (Switzerland) as an advisor to the Waypoint Capital group before taking up her position at Gurnet Point’s headquarters in Cambridge, Massachusetts later this year. Waypoint Capital advises the trusts and funds associated with the Bertarelli family, the principal investors in Gurnet Point Capital.
About Gurnet Point Capital
Gurnet Point Capital is a unique healthcare fund founded by Ernesto Bertarelli and led by Christopher A. Viehbacher, who, together, have decades of expertise in an industry for which they share a passion, both as Chief Executives and as investors. With an initial allocation of $2 billion, Gurnet Point is investing long-term capital and supporting entrepreneurs in building a new generation of companies. Based in Cambridge, MA, its remit is global, encompassing life sciences and medical technologies. The fund invests across all stages of product development through to commercialisation and does so with an approach that is a hybrid of venture and private equity investing strategies.